Wendy L. Dixon - 15 Mar 2024 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Reporting relationship: Director
Issuer ticker: BDTX
Reported as of: 15 Mar 2024
Net transaction value: +$14,769
SEC form: 4
Accepted by SEC: 03 Apr 2024, 20:49:49 UTC
Prior SEC filing: 15 Dec 2023
Next SEC filing: 15 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact

Key filing fact

Wendy L. Dixon filed Form 4 for Black Diamond Therapeutics, Inc. (BDTX) on 03 Apr 2024.

Key facts

This page summarizes Wendy L. Dixon's Form 4 filing for Black Diamond Therapeutics, Inc. (BDTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Apr 2024, 20:49.

Change

Previous filing in this sequence was filed on 15 Dec 2023.
Current net transaction value: +$14,769.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDTX transaction

Common Stock

Award

Transaction value: $14,769
Shares: +3,253
Change %: +9.3%
Price: $4.54
Shares after: 38,054
Date: 15 Mar 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

Footnote F2

The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 14, 2024.